Prophase Labs Stock Analysis
PRPH Stock | USD 0.42 0.03 6.04% |
ProPhase Labs is undervalued with Real Value of 4.94 and Target Price of 18.5. The main objective of ProPhase Labs stock analysis is to determine its intrinsic value, which is an estimate of what ProPhase Labs is worth, separate from its market price. There are two main types of ProPhase Labs' stock analysis: fundamental analysis and technical analysis.
The ProPhase Labs stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ProPhase Labs' ongoing operational relationships across important fundamental and technical indicators.
ProPhase |
ProPhase Stock Analysis Notes
About 14.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.29. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. ProPhase Labs recorded a loss per share of 1.53. The entity last dividend was issued on the 24th of May 2022. The firm had 2:1 split on the 23rd of January 1997. ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Prophase Labs operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 129 people. To find out more about ProPhase Labs contact Ted Karkus at 215 345 0919 or learn more at https://www.prophaselabs.com.ProPhase Labs Quarterly Total Revenue |
|
ProPhase Labs Investment Alerts
ProPhase Labs generated a negative expected return over the last 90 days | |
ProPhase Labs has high historical volatility and very poor performance | |
ProPhase Labs has some characteristics of a very speculative penny stock | |
The company reported the previous year's revenue of 44.38 M. Net Loss for the year was (16.78 M) with loss before overhead, payroll, taxes, and interest of (1.64 M). | |
ProPhase Labs currently holds about 27.5 M in cash with (11.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Roughly 14.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from news.google.com: ProPhase Labs stock hits 52-week low at 0.41 amid sharp decline - MSN |
ProPhase Labs Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ProPhase Labs previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
26th of March 2024 Upcoming Quarterly Report | View | |
9th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
26th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
ProPhase Largest EPS Surprises
Earnings surprises can significantly impact ProPhase Labs' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2004-10-28 | 2004-09-30 | 0.02 | 0.03 | 0.01 | 50 | ||
1997-08-13 | 1997-06-30 | 0.08 | 0.07 | -0.01 | 12 | ||
2010-11-10 | 2010-09-30 | 0.09 | 0.06 | -0.03 | 33 |
ProPhase Labs Thematic Classifications
In addition to having ProPhase Labs stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Health ManagementHealthcare providers, hospitals | ||
ManagementManagement services |
ProPhase Stock Institutional Investors
Shares | Bank Of America Corp | 2024-09-30 | 36.7 K | Bridgeway Capital Management, Llc | 2024-09-30 | 23.1 K | T. Rowe Price Associates, Inc. | 2024-09-30 | 17.3 K | Commonwealth Equity Services Inc | 2024-09-30 | 13.4 K | Two Sigma Securities, Llc | 2024-09-30 | 12 K | Barclays Plc | 2024-09-30 | 11.8 K | Ubs Group Ag | 2024-09-30 | 10.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 4.4 K | Jamison Private Wealth Management Inc | 2024-09-30 | 3 K | Vanguard Group Inc | 2024-09-30 | 655.9 K | Renaissance Technologies Corp | 2024-09-30 | 215.1 K |
ProPhase Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.7 M.ProPhase Profitablity
The company has Profit Margin (PM) of (1.46) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.16) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.16.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.20) | (0.19) | |
Return On Capital Employed | (0.35) | (0.33) | |
Return On Assets | (0.18) | (0.16) | |
Return On Equity | (0.31) | (0.29) |
Management Efficiency
ProPhase Labs has return on total asset (ROA) of (0.2298) % which means that it has lost $0.2298 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5092) %, meaning that it created substantial loss on money invested by shareholders. ProPhase Labs' management efficiency ratios could be used to measure how well ProPhase Labs manages its routine affairs as well as how well it operates its assets and liabilities. The ProPhase Labs' current Return On Tangible Assets is estimated to increase to -0.19. The ProPhase Labs' current Return On Capital Employed is estimated to increase to -0.33. As of now, ProPhase Labs' Other Current Assets are decreasing as compared to previous years. The ProPhase Labs' current Intangible Assets is estimated to increase to about 14.9 M, while Total Current Assets are projected to decrease to under 27.5 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 3.30 | 1.90 | |
Tangible Book Value Per Share | 2.13 | 1.73 | |
Enterprise Value Over EBITDA | (7.57) | (7.19) | |
Price Book Value Ratio | 1.81 | 1.72 | |
Enterprise Value Multiple | (7.57) | (7.19) | |
Price Fair Value | 1.81 | 1.72 | |
Enterprise Value | 19.4 M | 18.4 M |
Effective leadership at ProPhase Labs drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Technical Drivers
As of the 30th of January, ProPhase Labs holds the Variance of 75.27, risk adjusted performance of (0.18), and Coefficient Of Variation of (436.11). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of ProPhase Labs, as well as the relationship between them.ProPhase Labs Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. ProPhase Labs middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for ProPhase Labs. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
ProPhase Labs Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProPhase Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProPhase Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ProPhase Labs insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ProPhase Labs Outstanding Bonds
ProPhase Labs issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ProPhase Labs uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ProPhase bonds can be classified according to their maturity, which is the date when ProPhase Labs has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
MPLX LP 4125 Corp BondUS55336VAK61 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
US74348YAV39 Corp BondUS74348YAV39 | View | |
PROSPECT CAP P Corp BondUS74348YDU29 | View | |
US74348YDX67 Corp BondUS74348YDX67 | View | |
BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
PROSPECT CAP P Corp BondUS74348YEA55 | View | |
US74348TAU60 Corp BondUS74348TAU60 | View |
ProPhase Labs Predictive Daily Indicators
ProPhase Labs intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ProPhase Labs stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Daily Balance Of Power | (9,223,372,036,855) | |||
Rate Of Daily Change | 0.94 | |||
Day Median Price | 0.42 | |||
Day Typical Price | 0.42 | |||
Price Action Indicator | (0.01) | |||
Period Momentum Indicator | (0.03) |
ProPhase Labs Forecast Models
ProPhase Labs' time-series forecasting models are one of many ProPhase Labs' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ProPhase Labs' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About ProPhase Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ProPhase Labs prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ProPhase shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ProPhase Labs. By using and applying ProPhase Stock analysis, traders can create a robust methodology for identifying ProPhase entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.59) | (0.56) | |
Operating Profit Margin | (0.56) | (0.53) | |
Net Loss | (0.34) | (0.32) | |
Gross Profit Margin | 0.42 | 0.58 |
Current ProPhase Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ProPhase analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ProPhase analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
18.5 | Strong Buy | 1 | Odds |
Most ProPhase analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ProPhase stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ProPhase Labs, talking to its executives and customers, or listening to ProPhase conference calls.
ProPhase Stock Analysis Indicators
ProPhase Labs stock analysis indicators help investors evaluate how ProPhase Labs stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ProPhase Labs shares will generate the highest return on investment. By understating and applying ProPhase Labs stock analysis, traders can identify ProPhase Labs position entry and exit signals to maximize returns.
Begin Period Cash Flow | 9.1 M | |
Total Stockholder Equity | 49.4 M | |
Capital Lease Obligations | 11.1 M | |
Property Plant And Equipment Net | 17.5 M | |
Cash And Short Term Investments | 4.7 M | |
Cash | 1.6 M | |
50 Day M A | 0.6756 | |
Net Interest Income | -841 K | |
Total Current Liabilities | 20.9 M | |
Forward Price Earnings | 10.0908 | |
Investments | -5.1 M | |
Interest Expense | 1.3 M | |
Stock Based Compensation | 3.5 M | |
Long Term Debt | 10.3 M | |
Common Stock Shares Outstanding | 17.2 M | |
Tax Provision | -5.8 M | |
Quarterly Earnings Growth Y O Y | -0.952 | |
Free Cash Flow | -14.5 M | |
Other Current Assets | 2.7 M | |
Accounts Payable | 9.4 M | |
Net Debt | 19.8 M | |
Other Operating Expenses | 66 M | |
Non Current Assets Total | 44.3 M | |
Liabilities And Stockholders Equity | 91.9 M | |
Non Currrent Assets Other | 2 M |
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
CEOs Directory Screen CEOs from public companies around the world | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Equity Valuation Check real value of public entities based on technical and fundamental data |